Clinical Trials on HIV-1 in United Kingdom

Total 10048 results

Ratiopharm GmbH

Completed

Multiple Dose BE Study With Nevirapine 400mg PR Tablets

HIV-1

United Kingdom
University of Oxford
Medical Research Council

Terminated

Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART

HIV-1

United Kingdom
Imperial College London

Active, not recruiting

Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens (EAVI2020_01)

HIV-1-infection

United Kingdom
Imperial College London
Medical Research Council

Terminated

Novel Interventions in HIV-1 Infection (IMIRC1003)

HIV-1 Infection

United Kingdom
University of Oxford

Completed

Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults (HIV-CORE 002)

HIV-1 Infections

United Kingdom
Guy's and St Thomas' NHS Foundation Trust
Gilead Sciences; ViiV Healthcare

Completed

The Role of Home Packs of HIV PEPSE in High Risk Individuals (Home PEPSE)

HIV-1-infection

United Kingdom
Brighton and Sussex University Hospitals NHS Trust
Merck Sharp & Dohme LLC

Completed

The Medicines Optimisation Review Toolkit Evaluation in HIV Outpatients (MOR)

HIV-1-infection

United Kingdom
Merck Sharp & Dohme LLC

Completed

Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)

HIV-1 Infection

Germany, United Kingdom
Chelsea and Westminster NHS Foundation Trust

Recruiting

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (DORDOL)

HIV-1-infection

United Kingdom
Objectif Recherche Vaccins SIDA
Merck Sharp & Dohme LLC; Pfizer; Cytheris SA

Completed

Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients (ERAMUNE-01)

HIV-1 Infection

United Kingdom, France, Italy, Spain
Kirby Institute

Completed

MARCH Central Nervous System Substudy

HIV-1 Infection

Argentina, Thailand, United Kingdom
University College, London
Medical Research Council; Royal Free Hospital NHS Foundation Trust; ViiV Healthcare

Completed

Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV (MAVMET)

Hepatic Steatosis | HIV-1-infection

United Kingdom
Bionor Immuno AS

Completed

Re-boosting of HIV-1 Infected Subjects With Vacc-4x (Re-boost)

HIV-1 Infection

United States, Spain, Germany, Italy, United Kingdom
ANRS, Emerging Infectious Diseases
Imperial College London; University College, London; Fred Hutchinson Cancer Center and other collaborators

Terminated

An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection (EHVAT01)

HIV-1-infection

Switzerland, United Kingdom
Chelsea and Westminster NHS Foundation Trust

Recruiting

The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

HIV-1-infection

United Kingdom
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)

HIV-1 Infection

France, United States, Spain, Ukraine, United Kingdom, Ireland
Gilead Sciences

Completed

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

HIV-1 Infection

France, United Kingdom, Spain, Belgium, Ireland
GlaxoSmithKline

Terminated

Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects

HIV-1

Australia, Belgium, Canada, France, Germany, Greece, Italy, Spain, United Kingdom
NEAT ID Foundation
ViiV Healthcare

Completed

An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N (WISARD)

HIV-1-infection

Spain, Belgium, France, Germany, Italy, United Kingdom
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
Gilead Sciences

Completed

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

HIV-1 Infection

Spain, United Kingdom, France, Italy, Belgium
Eunice Kennedy Shriver National Institute of Child...

Completed

Interventions to Decrease the Risk of Mother-to-Child Transmission of HIV in India

HIV-1

United States
Janssen Sciences Ireland UC

Completed

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

HIV-1 Infections

France, Ukraine, South Africa, United Kingdom, Argentina, Brazil, India, Spain
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
Pfizer

Terminated

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

HIV-1

Spain, United Kingdom, Malaysia, United States, Portugal, Brazil, Germany, Italy, Poland, Puerto Rico, South Africa, Taiwan, Ukraine
Janssen Research & Development, LLC

Completed

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

HIV-1

United States
Chelsea and Westminster NHS Foundation Trust

Completed

The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers (DTG Clamp)

HIV-1-infection on Healthy Volunteers

United Kingdom
Janssen Pharmaceutica N.V., Belgium

Completed

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

HIV-1

United States, Spain
Pfizer

Completed

A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1

HIV-1

United Kingdom, South Africa, Australia, Canada, Italy, Poland, Switzerland, Argentina, Mexico
Pfizer
ViiV Healthcare

Terminated

A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1

HIV-1

United States, United Kingdom, Portugal, Ukraine, Italy, Poland, Switzerland, Argentina, South Africa, Puerto Rico, Brazil, Malaysia
ViiV Healthcare
Pfizer

Completed

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine (MERIT)

HIV-1

United States, Canada, United Kingdom, Netherlands, Argentina, Australia, Belgium, South Africa, Switzerland, Italy, Puerto Rico, Brazil, Mexico, Poland
Gilead Sciences

Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

HIV-1 Infection

Spain, United Kingdom, Italy, France, Belgium
Nina Bhardwaj
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaborators

Completed

Enhancement by Poly-ICLC During HIV-1 Infection (Poly-ICLC)

HIV-1 Infected Adults With Chronic HIV-1 Infection

United States
ViiV Healthcare
Pfizer

Terminated

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 (MODERN)

HIV-1

United States, Netherlands, Spain, Puerto Rico, Canada, Australia, Germany, Sweden, Poland, Portugal, Switzerland, France, Denmark, Italy, Belgium, United Kingdom, Hungary, Austria, Finland
Pfizer
ViiV Healthcare

Terminated

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

HIV-1

South Africa, Australia, United Kingdom, Canada, Italy, Poland, Switzerland, Mexico, Brazil
Gilead Sciences

Completed

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

HIV-1 Infection

Spain, United Kingdom, France, Germany, United States, Italy
Tibotec Pharmaceuticals, Ireland

Completed

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

HIV-1

United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia
ANRS, Emerging Infectious Diseases
University College London Hospitals; Hospital Clinic of Barcelona; Imperial College... and other collaborators

Completed

A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)

HIV-1-infection

France, United Kingdom, Switzerland
University of Sheffield

Completed

Lifestyle Matters: An Occupational Approach Towards Health and Well-being in Later Life

Mental Health Wellness 1

United Kingdom
Oxford Brookes University
University of Oxford

Completed

Physical Exercise for Education ('Fit to Study') (FTS)

Physical Activity | Mental Health Wellness 1 | Cognitive Function 1, Social | Academic Attainment | Fitness Testing

United Kingdom
Johns Hopkins Bloomberg School of Public Health
National Institute on Drug Abuse (NIDA)

Completed

Providing Unique Support for Health (PUSH) Study

HIV-1-infection

United States
Environment and Health Group, Inc.
Prisma Health

Completed

mHealth for ART Adherence by HIV+ African Americans

HIV-1-infection

United States
Rush University Medical Center
Merck Sharp & Dohme LLC

Withdrawn

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women (ICE-002)

HIV-1 Infections

United States
City of Hope Medical Center

Terminated

Gene Transfer for HIV Using Autologous T Cells (Gene Transfer)

HIV-1 Infection

United States
Brigham and Women's Hospital
Merck Sharp & Dohme LLC

Terminated

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy

HIV-1 Infection

United States
Bristol-Myers Squibb

Completed

Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

HCV (Genotype 1)

United States, Puerto Rico
Viriom

Completed

Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects

HIV-1-infection

United States
Southampton Healthcare, Inc.

Terminated

Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

HIV-1-infection

United States
Calimmune, Inc.

Active, not recruiting

Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients

HIV-1 Infection | Receipt of Cal-1 Modified Hematopoietic Cellular Products

United States
University of Bath
Arla Foods

Completed

The Dose Response of Calcium Co-ingested With Protein on GLP-1 Concentrations (PROCAL)

GLP-1 Concentration

United Kingdom

Clinical Trials on HIV-1 in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations